Chi Sheng Pharma & Biotech Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chi Sheng Pharma & Biotech.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	48.0%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Chi Sheng Pharma & Biotech onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

TPEX:4111 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (TWD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	1,082	73	24	132	N/A
3/31/2024	1,065	73	-67	47	N/A
12/31/2023	1,061	69	-27	75	N/A
9/30/2023	1,090	116	9	111	N/A
6/30/2023	1,115	151	89	197	N/A
3/31/2023	1,130	164	107	225	N/A
12/31/2022	1,143	179	109	215	N/A
9/30/2022	1,105	186	128	216	N/A
6/30/2022	1,085	150	-73	197	N/A
3/31/2022	1,059	129	-100	164	N/A
12/31/2021	1,022	108	-126	139	N/A
9/30/2021	1,003	56	-137	125	N/A
6/30/2021	971	41	61	103	N/A
3/31/2021	953	46	87	109	N/A
12/31/2020	979	59	121	144	N/A
9/30/2020	1,005	72	101	129	N/A
6/30/2020	1,026	80	152	177	N/A
3/31/2020	1,047	85	179	206	N/A
12/31/2019	1,023	72	126	163	N/A
9/30/2019	998	57	131	187	N/A
6/30/2019	985	57	69	134	N/A
3/31/2019	964	46	18	87	N/A
12/31/2018	967	42	38	114	N/A
9/30/2018	985	52	34	98	N/A
6/30/2018	1,016	60	63	133	N/A
3/31/2018	1,032	69	N/A	157	N/A
12/31/2017	1,045	82	N/A	181	N/A
9/30/2017	1,034	91	N/A	162	N/A
6/30/2017	1,012	88	N/A	160	N/A
3/31/2017	995	85	N/A	133	N/A
12/31/2016	964	73	N/A	104	N/A
9/30/2016	946	48	N/A	130	N/A
6/30/2016	936	46	N/A	120	N/A
3/31/2016	938	42	N/A	116	N/A
12/31/2015	932	39	N/A	97	N/A
9/30/2015	908	40	N/A	92	N/A
6/30/2015	922	50	N/A	89	N/A
3/31/2015	925	59	N/A	116	N/A
12/31/2014	943	73	N/A	147	N/A
9/30/2014	979	104	N/A	167	N/A
6/30/2014	974	105	N/A	177	N/A
3/31/2014	960	106	N/A	188	N/A
12/31/2013	921	96	N/A	143	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if 4111's forecast earnings growth is above the savings rate (1%).

Winst versus markt: Insufficient data to determine if 4111's earnings are forecast to grow faster than the TW market

Hoge groeiwinsten: Insufficient data to determine if 4111's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if 4111's revenue is forecast to grow faster than the TW market.

Hoge groei-inkomsten: Insufficient data to determine if 4111's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if 4111's Return on Equity is forecast to be high in 3 years time

Chi Sheng Pharma & Biotech Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.36 in 2Q 2023)

Dividend reduced to NT$1.00

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 23%

Now 28% overvalued after recent price rise

First quarter 2024 earnings released: EPS: NT$0.41 (vs NT$0.33 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$1.21 (vs NT$3.15 in FY 2022)

Chi Sheng Pharma & Biotech Co., Ltd, Annual General Meeting, Jun 13, 2024

New minor risk - Profit margin trend

Upcoming dividend of NT$1.20 per share at 4.5% yield

Second quarter 2023 earnings released: EPS: NT$0.36 (vs NT$0.46 in 2Q 2022)

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: NT$3.14 (vs NT$1.42 in FY 2021)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS NT$0.39 (vs NT$0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.21 (vs NT$0.28 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.46 in 1Q 2020)

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Full year 2020 earnings released: EPS NT$1.04 (vs NT$1.27 in FY 2019)

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$22.80

New 90-day low: NT$23.30

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Third quarter 2020 earnings released: EPS NT$0.14

New 90-day low: NT$24.00

New 90-day low - NT$24.40

First half earnings released

First half earnings released

New 90-day low - NT$25.55

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven